Mdma molecule:

Image from PubChem

Mdma Clinical Trials

Phase II Pilot Randomized Double-Blind Placebo-Controlled Study of 3,4-methylenedioxymethamphetamine (MDMA)Assisted Psychotherapy in Posttraumatic Stress Disorder (PTSD)- Switzerland

To see complete record on, please visit this link

Id: NCT00353938

Organisation Name: Multidisciplinary Association for Psychedelic Studies

Overal Status: Completed

Start Date: October 2006

Last Update: July 6, 2022

Lead Sponsor: Multidisciplinary Association for Psychedelic Studies

Brief Summary: This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

  • Posttraumatic Stress Disorder

Total execution time in seconds: 0.43710708618164